Phase II study of pegaspargase, etoposide, gemcitabine (PEG) followed by involved-field radiation therapy in early-stage extranodal natural killer/T-cell lymphoma
PEG followed by IFRT is a safe and effective initial therapy for early-stage ENKTL, demonstrating impressive PFS and OS rates. This promising approach warrants further validation in a randomized controlled trial (Registered at Clinicaltrials.gov NCT02705508).<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT02705508.
Authors
- Demei Feng (ORCID: https://orcid.org/0009-0004-7038-3673)
- Bibo Fu
- Shenrui Bai (ORCID: https://orcid.org/0000-0002-2804-6292)
- Zhimin Yan (ORCID: https://orcid.org/0000-0002-0751-7374)
- Robert Peter Gale (ORCID: https://orcid.org/0000-0002-9156-1676)
- Hua Wang (ORCID: https://orcid.org/0000-0002-2605-5697)
- Lewei Zhu
- Yang Liang
- Zhongjun Xia
Institutions
- Sun Yat-sen University (CN)
- First People's Hospital of Foshan (CN)
- First Affiliated Hospital of Gannan Medical University (CN)
- Sun Yat-sen University Cancer Center (CN)
- Imperial College London (GB)
Publication Details
- Journal
- Hematology
- Published
- 2024-09-13
- DOI
- https://doi.org/10.1080/16078454.2024.2402102
- Citations
- 1
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- Guangdong Innovative and Entrepreneurial Research Team Program
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- National Natural Science Foundation of China-Guangdong Joint Fund
- Sun Yat-sen University Cancer Center